Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently approved for the treatment of type 2 diabetes mellitus, obesity, and obstructive sleep apnea, have recently emerged as potential new pharmacotherapies for ASUDs
The FDA label states that providers should consider discontinuing treatment if patients do not achieve at least 5% weight loss after 12 weeks at the maintenance dose, as continued use is unlikely to provide meaningful clinical benefit
Eitinger T
doi:10.2147/CCID.S128339 Watanabe F, Hashizume E, Chan GP, Kamimura A
Development of composite PLGA microspheres containing exenatide-encapsulated lecithin nanoparticles for sustained drug release
US$ 21.23
US$ 27.32
US$ 20.02
US$ 25.42
US$ 29.60
US$ 26.28
US$ 24.04
